Viral vector stabilization
Combining viral vector with surfactant preserves vector infectivity, and surfactant provided an unexpected benefit by protecting viral vector from damage due to transient elevated temperature.
1. A method of treating a human subject, the method comprising:
a. obtaining a surfactant having Structure I:
b. obtaining a recombinant adenovirus comprising a transgene and having infectivity;
c. mixing the adenovirus with the surfactant to form an admixture;
d. storing the admixture at about 4° C. or room temperature for at least about one week, wherein after said storage the adenovirus retains a higher level of infectivity relative to control; and
e. contacting human cells with the admixture, thereby treating the human subject in need thereof.
2. The method of claim 1 , wherein the adenovirus comprises an attenuated adenovirus.
3. The method of claim 1 , wherein the transgene encodes interferon.
4. The method of claim 1 , wherein the transgene encodes interferon alpha-2b.
5. The method of claim 4 , wherein the contacting step comprises providing a gene therapy comprising the admixture.
6. The method of claim 1 , wherein the admixture is stored at about 4° C. or room temperature for at least about three months.
7. The method of claim 1 , wherein the admixture is stored at about 4° C. or room temperature for at least about twelve months.
8. The method of claim 5 , wherein the adenovirus is replication-deficient and cannot replicate in normal human cells.
9. The method of claim 8 , wherein the admixture is stored at about 4° C. or room temperature for at least about three months.
10. The method of claim 8 , wherein the admixture is stored at about 4° C. or room temperature for at least about twelve months.
11. The method of claim 1 , wherein the adenovirus is a type 5 adenovirus.
12. The method of claim 8 , wherein the adenovirus is a type 5 adenovirus.